Sysmex Nederland
Menu

Colorectal cancer

Earlier recognition. Better survival rates. Synergy in expertise.

Over 400,000 of new cases of colorectal cancer are diagnosed in Europe each year. Yet early recognition, individualising cancer therapy, and using less invasive diagnostics are leading to improved prognoses and greater quality of life. Identifying the cancer early on is especially important for therapeutic success. Screening – both symptomatic and especially large-scale – is essential.

Everything we offer is designed to help clinicians, laboratories and physicians that adress screening, diagnosis and therapy of colorectal cancer disease.

Screening

The quantitative FOB Gold FIT (Faecal immunological testing) screening test delivers more reliable results than the standard qualitative test. Extremely flexible, it can be adapted to screening programmes of any size and to laboratories with all throughputs.

Diagnostics

When determining therapy, often whether to give chemotherapy or not, the stage of the cancer is decisive. Sensitive, standardised lymph node diagnostics and the resulting nodal status are essential here. OSNA delivers the sensitivity and standardisation required and reduces false-negatives compared to classic histopathology.

Therapy

Using antibodies alongside chemotherapy has improved the overall survival of CRC patients.1 But clinicians must test stringently which patients are eligible. The OncoBEAMTM RAS CRC test uses a blood sample instead of tumour tissue and overcomes the limitations of tissue biopsies like sample availability, turnaround time and tumour heterogeneity.

Discover our solutions in colorectal cancer

Discover our videos

Walk-Away FIT solutions for high throughput

Walk-Away FIT solutions for high throughput

Colorectal cancer monitoring

A step forward in colorectal cancer monitoring

Go Beyond Biopsy with Blood

Go Beyond Biopsy with Blood - BEAMing Digital PCR

Our solutions

CALiaGold

CALiaGold

Quantitative latex immunoassay for calprotectin measurement

Details
FOB Gold pierce tube

FOB Gold pierce tube

From faecal sample collection to direct analysis.

Details
SENTiFIT 270

SENTiFIT 270

The fully automated and dedicated system for quantitative FIT

Details
SENTiFOB analyser

SENTiFOB analyser

The automated solution for a hygienic FIT measurement (low workload)

Details
Walk-Away Solutions

Walk-Away Solutions

High throughput needs of large-scale screening programs with centralised lab testing settings.

Details

Literature

  1. Lee J.J. et al. (2016): Options for Second-Line Treatment in Metastatic Colorectal Cancer. Clinical Advances in Hematology & Oncology, 14(1):46-54.
Copyright © Sysmex Europe SE. All rights reserved.